Exscientia (NASDAQ:EXAI) Trading Up 4.7%

Exscientia plc (NASDAQ:EXAIGet Free Report)’s stock price was up 4.7% on Tuesday . The company traded as high as $6.00 and last traded at $5.98. Approximately 93,902 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 623,951 shares. The stock had previously closed at $5.71.

Analysts Set New Price Targets

A number of analysts have recently weighed in on EXAI shares. Morgan Stanley reiterated an “equal weight” rating and issued a $7.00 price objective on shares of Exscientia in a research note on Monday, April 22nd. TD Cowen initiated coverage on shares of Exscientia in a research report on Tuesday. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.75.

Read Our Latest Stock Report on EXAI

Exscientia Trading Down 1.5 %

The company’s 50-day moving average price is $5.16 and its 200-day moving average price is $5.61. The firm has a market cap of $692.70 million, a price-to-earnings ratio of -4.37 and a beta of 0.84. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.05.

Exscientia (NASDAQ:EXAIGet Free Report) last announced its earnings results on Tuesday, May 21st. The company reported ($0.21) earnings per share (EPS) for the quarter. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. The company had revenue of $6.70 million during the quarter. Equities analysts expect that Exscientia plc will post -1.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Exscientia

Several hedge funds and other institutional investors have recently modified their holdings of EXAI. Banque Pictet & Cie SA purchased a new position in Exscientia during the third quarter worth about $1,040,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Exscientia in the fourth quarter valued at approximately $207,000. New Republic Capital LLC acquired a new position in shares of Exscientia in the fourth quarter valued at approximately $128,000. Jump Financial LLC grew its holdings in shares of Exscientia by 47.7% in the fourth quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock valued at $345,000 after purchasing an additional 17,355 shares in the last quarter. Finally, Colonial River Wealth Management LLC acquired a new position in shares of Exscientia in the fourth quarter valued at approximately $86,000. 41.58% of the stock is owned by hedge funds and other institutional investors.

About Exscientia

(Get Free Report)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

Recommended Stories

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.